Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Taiwan · Delayed Price · Currency is TWD

145.50

+6.50 (4.68%)

At close: Sep 7, 2026

Market Cap	19.54B
Revenue (ttm)	113.34M +10,946.9%
Net Income	-155.83M
EPS	-1.17
Shares Out	134.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,860,087
Open	140.50
Previous Close	139.00
Day's Range	137.00 - 152.50
52-Week Range	37.55 - 153.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About TPEX:7871

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of immunotherapies for cancer and immune diseases in the United States. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and hemophagocytic lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. It also offers mRNA drug development platform, which focuses on in-vivo expression of biologics, accelera... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2017

Country Cayman Islands

Stock Exchange Taipei Exchange

Ticker Symbol 7871

Full Company Profile

Financial Performance

In 2025, TPEX:7871's revenue was 50.29 million, an increase of 6162.39% compared to the previous year's 803,000. Losses were -1.11 billion, 151.3% more than in 2024.

Financial Statements